Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program

Core Insights - Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is recognized as a promising stock under $5 with potential for significant growth [1] - Analysts at Wedbush have raised the price target for BDTX from $13 to $14, maintaining an "Outperform" rating due to optimism regarding the company's clinical pipeline and upcoming catalysts [2] Clinical Progress - The company is focused on precision oncology, with notable advancements in the silevertinib program, which has positively influenced share price performance [3] - Preliminary Phase 2 data for silevertinib in NSCLC patients with uncommon EGFR mutations was reported in December 2025, with further data expected soon, serving as a key catalyst for the stock [3] Financial Performance - For the fourth quarter and full year ending December 31, 2025, BDTX reported a 60% objective response rate, 86% CNS objective response rate, and 91% disease control rate from Phase 2 data [4] - The company has increased cash reserves to $128.7 million and reported a net income of $22.4 million, with a financial runway extending into the second half of 2028 [4] Company Overview - Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target oncogenic mutations, particularly focusing on brain-penetrant EGFR inhibitors for NSCLC and glioblastoma [5]